Every Form 4 that Akero Therapeutics, Inc. (AKRO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AKRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKRO filings page.
Akero Therapeutics’ Chief Scientific Officer reported the completion of a merger in which Novo Nordisk A/S acquired Akero through a cash-and-contingent value right structure. At the effective time on December 9, 2025, each share of Akero common stock held by the officer was cancelled and converted into the right to receive $54.00 in cash plus one contractual contingent value right that may pay $6.00 in cash if a specified milestone is achieved.
The report also shows that the officer’s restricted stock units became fully vested at closing and were converted into the same merger consideration for each underlying share. All compensatory stock options to purchase Akero common stock, whether vested or unvested, were cancelled and converted into a cash payment based on the excess of the $54.00 cash price over each option’s exercise price, plus one contingent value right for each underlying share, in line with the merger agreement.
Akero Therapeutics, Inc. Chief Operating Officer Form 4 activity reports stock option exercises and a charitable gift of common stock. On 11/24/2025, the reporting person exercised three stock option grants, acquiring 4,284 shares at an exercise price of $21.09, 3,527 shares at $28.35, and 4,739 shares at $21.10. After these exercises, direct holdings increased, and following the reported transactions the person directly owned 200,189 shares of Akero common stock.
On 11/26/2025, the individual reported a transaction coded as a gift, transferring 9,259 shares of common stock at a reported price of $0 to a donor advised fund. In addition to direct ownership, the filing shows indirect ownership of 20,000 Akero shares in each of three irrevocable trusts for the benefit of the reporting person’s children, for a total of 60,000 indirectly held shares. The reporting person disclaims beneficial ownership of the trust-held securities, and notes that the stock options exercised are vested and currently exercisable.
Akero Therapeutics, Inc. insider ownership changed due to a charitable gift. The company’s President, CEO, and director reported donating 74,538 shares of Akero Therapeutics common stock as a gift to a donor advised fund on 11/20/2025. The transaction was reported with a price of $0, consistent with a non-cash charitable transfer rather than a market sale.
Following this gift, the reporting person directly beneficially owns 436,837 shares of Akero Therapeutics common stock. This Form 4 filing documents the change in beneficial ownership for regulatory disclosure purposes and does not describe any open-market purchase or sale.
Akero Therapeutics (AKRO) reported an insider stock gift by its Chief Scientific Officer. On 11/17/2025, the executive donated 37,100 shares of Akero common stock as a gift to a donor advised fund, with the transaction reported at a price of $0 per share, reflecting the non-sale nature of the transfer. After this charitable transfer, the reporting person beneficially owns 129,471 shares of Akero common stock in direct ownership form. This filing documents a change in the executive’s personal holdings without involving an open-market sale or purchase of shares.
Akero Therapeutics (AKRO) reported an insider transaction by its President and CEO, who is also a Director. On 11/12/2025, the insider made a bona fide charitable gift of 14,739 shares of common stock, reported as code G at a stated price of $0. Following the transaction, the insider’s beneficial ownership stands at 511,375 shares, held directly.
The explanation notes the recipient is a 501(c)(3) organization and the reporting person has no pecuniary interest in that entity.
Akero Therapeutics (AKRO) disclosed an insider transaction by its Chief Development Officer. On 11/04/2025, the officer exercised stock options and acquired 3,527 shares at $28.35 and 4,739 shares at $21.10 (code M). Following these transactions, the officer reported ownership of 74,800 shares, held directly.
A footnote states the reported amount was adjusted to correct a prior overstatement of common stock ownership. Another footnote confirms the options were vested and currently exercisable.
Akero Therapeutics (AKRO) reported an insider transaction by its President and CEO, who is also a director. On 10/10/2025, the executive exercised 30,000 stock options at an exercise price of $19.87 per share and sold 30,000 shares of common stock at a $53.978 weighted-average price.
The transactions were effected under a Rule 10b5-1 trading plan dated August 16, 2024. Following the sale, the executive held 526,114 shares of common stock directly and 380,017 derivative securities (options) beneficially owned. The option grant vests in 48 equal monthly installments commencing on December 8, 2023.
Akero Therapeutics (AKRO) director Graham G. Walmsley reported multiple option exercises and acquisitions on 10/08/2025 that increased his direct holdings to 93,000 common shares and reflect an indirect interest of 1,200,000 shares held by affiliated funds. The filing lists five option exercises covering 90,832 shares (strike prices from $8.13 to $26.32) and corresponding non‑derivative acquisitions at prices between $8.13 and $26.32. All reported options are noted as vested and exercisable, and the indirect position is held through Logos Master Fund and Logos Opportunities Fund IV with the reporting person as a managing member of the affiliated general partners.
The transactions were disclosed on a single Form 4 filed by one reporting person; the filer disclaims beneficial ownership except for pecuniary interest. The signature block shows the form was signed by an attorney‑in‑fact on 10/10/2025.
Akero Therapeutics (AKRO) Form 4 shows Chief Scientific Officer Timothy Rolph used a Rule 10b5-1 plan to exercise 12,500 vested stock options at an exercise price of $28.35 and immediately sold those shares in multiple transactions on 10/07/2025. The sale comprised 11,463 shares at a weighted-average price of $46.013 and 1,037 shares at a weighted-average price of $46.822, leaving the reporting person with 166,571 shares beneficially owned and 49,945 options outstanding after the transactions. The filing cites a previously adopted Rule 10b5-1 trading plan dated 08/12/2024 and confirms the exercised options were vested and exercisable.
Andrew Cheng, who serves as President and CEO and a director of Akero Therapeutics, Inc. (AKRO), reported a change in beneficial ownership dated 10/08/2025. The filing shows an acquisition of 52,212 shares/options at a price of $0.615 per share, and after the reported transaction Mr. Cheng beneficially owns 526,114 shares. The document also discloses a derivative entry for 52,212 stock options with the same exercise price; the filer notes these options are vested and currently exercisable. The Form is signed by an attorney-in-fact on 10/09/2025.
Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 plan. He acquired 12,500 stock options at an exercise price of $21.10 and exercised options that resulted in ownership of 82,482 common shares in total. On the same date he sold 12,500 common shares via a market sale at a weighted-average price of $21.10 (option acquisition) and separately sold 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at a weighted-average price of $47.984. Following the reported transactions, he directly beneficially owned 196,898 shares. He also holds indirect interests of 20,000 shares each through three irrevocable trusts for his children, which he disclaims as beneficial ownership.